Crystal structure of the T315I Abl mutant in complex with the Aurora kinases inhibitor PHA-739358

Cancer Research

Volumn 67, Issue 17, 2007, Pages 7987-7990

  Modugno, Michele ^a   Casale, Elena ^a   Soncini, Chiara ^a   Rosettani, Pamela ^a   Colombo, Riccardo ^a   Lupi, Rosita ^a   Rusconi, Luisa ^a   Fancelli, Daniele ^a   Carpinelli, Patrizia ^a   Cameron, Alexander D ^a   Isacchi, Antonella ^a   Moll, Jürgen ^a  

^a NERVIANO MEDICAL SCIENCES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; AURORA KINASE INHIBITOR; GENE PRODUCT; ISOLEUCINE; PHA 739358; T315I PROTEIN; THREONINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG IDENTIFICATION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME CONFORMATION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IN VITRO STUDY; MUTANT; PRIORITY JOURNAL; PROTEIN DOMAIN; WILD TYPE;

BENZAMIDES; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, MOLECULAR; MUTANT PROTEINS; PIPERAZINES; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-ABL; PYRAZOLES; PYRIMIDINES;

EID: 34548548332     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1825     Document Type: Article

References (19)

1. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105:2640-53.
2. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 2000;289:1938-42.
3. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-41.
4. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542-51.
5. + neoplastic cells. Cancer Res 2006;66:11314-22.
6. Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci U S A 2005;102:3395-400.
7. von Bubnoff N, Manley PW, Mestan J, Sanger J, Peschel C, Duyster J. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 2006;108:1328-33.
8. Bradeen HA, Eide CA, O'Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl- N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006;108:2332-8.
9. Weisberg E, Manley PW, Cowan-Jacob SW, et al. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007;7:345-56.
10. Young MA, Shah NP, Chao LH, et al. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 2006;66:1007-14.
11. Giles FJ, Cortes JE, Jones D, Bergstrom DA, Kantarjian HM, Freedman SJ. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2006;109:500-2.
12. Otwinowski Z, Minor W. Macromolecular crystallography, part A. Methods Enzymol 1997;276:307-26.
13. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 1994;50:760-3.
14. Jones TA, Zou JY, Cowan SW, Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr D 1991;47:110-9.
15. Brunger AT, Adams PD, Clore GM, et al. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 1998;54:905-21.
16. Fancelli D, Moll J, Varasi M, et al. 1,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J Med Chem 2006;49:7247-51.
17. Corbin AS, La Rosee P, Stoffregen EP, Druker BJ, Deininger MW. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 2003;101:4611-4.
18. Fabian MA, Biggs WH III, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23:329-36.
19. Tokarski JS, Newitt JA, Chang CYJ, et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006;66:5790-7.